Cost-effectiveness and Budget Impact Analysis of Coronary CT Angiography in the Brazilian Unified Health System
Authors:
- Isabela Bispo Santos da Silva CostaICIsabela Bispo Santos da Silva Costa
- Jorge A. TorreãoJTJorge A. Torreão
- Afonso ShiozakiASAfonso Shiozaki
- Henrique Simão TradHTHenrique Simão Trad
- Marcio S. BittencourtMBMarcio S. Bittencourt
- Miguel Antônio MorettiMMMiguel Antônio Moretti
- Silvio Henrique BarberatoSBSilvio Henrique Barberato
- Carlos E. RochitteCRCarlos E. Rochitte
Open Access
- 1 January 2026
- journal article
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (9)
Abstract
Background Coronary artery disease (CAD) represents a major clinical and economic burden for the Brazilian Unified Health System (SUS). Although coronary computed tomography angiography (CCTA) has excellent diagnostic accuracy, cost-effectiveness analyses (CEA) based on national data are lacking. Objective To evaluate the cost-effectiveness and budget impact of incorporating CCTA as the initial diagnostic strategy for patients with suspected stable CAD from the SUS perspective. Methods A cost-effectiveness analysis (CEA) and a budget impact analysis (BIA) were conducted, comparing CCTA with invasive coronary angiography (ICA) and with a panel of functional tests in patients with suspected stable CAD. A one-year time horizon was adopted for the CEA and five years for the BIA. Effectiveness outcomes included the incidence of acute myocardial infarction (AMI), revascularization rates, and hospitalizations. Deterministic and probabilistic sensitivity analyses were performed. Results CCTA proved to be cost-effective, reducing costs related to AMI (R$610.18 vs. R$867.80), revascularization (R$1,378.14 vs. R$1,833.84), and hospitalization (R$602.86 vs. R$932.79), resulting in savings of R$329.93 per patient. Compared with functional tests, CCTA also reduced costs associated with AMI (R$610.18 vs. R$658.36), revascularization (R$1,378.14 vs. R$1,659.18), and hospitalization (R$602.86 vs. R$628.16). The BIA projected cumulative savings for SUS ranging from R$34.1 million to R$73 million over five years, depending on the comparator and diffusion scenario. Conclusions The results suggest that using CCTA as the initial diagnostic test for patients with low-to-moderate risk of CAD in SUS may represent an economically favorable strategy, with potential to generate substantial cost savings compared with the evaluated alternatives.This publication has 13 references indexed in Scilit:
- CT or Invasive Coronary Angiography in Stable Chest PainNew England Journal of Medicine, 2022
- Cardiac computed tomographic angiography after abnormal ischemia test as a gatekeeper to invasive coronary angiographyThe International Journal of Cardiovascular Imaging, 2022
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluationsBJOG: An International Journal of Obstetrics & Gynaecology, 2022
- Cost-effectiveness Analysis of Anatomic vs Functional Index Testing in Patients With Low-Risk Stable Chest PainJAMA Network Open, 2020
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromesEuropean Heart Journal, 2019
- Selective Referral Using CCTA Versus Direct Referral for Individuals Referred to Invasive Coronary Angiography for Suspected CADJACC: Cardiovascular Imaging, 2019
- Coronary CT Angiography and 5-Year Risk of Myocardial InfarctionNew England Journal of Medicine, 2018
- Chest pain of recent onset: assessment and diagnosis (CG95). A step change in the requirement for cardiovascular CTClinical Radiology, 2017
- CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trialThe Lancet, 2015
- Outcomes of Anatomical versus Functional Testing for Coronary Artery DiseaseNew England Journal of Medicine, 2015